Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: A randomised study

Christophe Hézode, Gideon M. Hirschfield, Wayne Ghesquiere, William Sievert, Maribel Rodriguez-Torres, Stephen D. Shafran, Paul J. Thuluvath, Harvey A. Tatum, Imam Waked, Gamal Esmat, Eric J. Lawitz, Vinod K. Rustgi, Stanislas Pol, Nina Weis, Paul J. Pockros, Marc Bourlière, Lawrence Serfaty, John M. Vierling, Michael W. Fried, Ola WeilandMaurizia R. Brunetto, Gregory T. Everson, Stefan Zeuzem, Paul Y. Kwo, Mark Sulkowski, Norbert Bräu, Dennis Hernandez, Fiona McPhee, Megan Wind-Rotolo, Zhaohui Liu, Stephanie Noviello, Eric A. Hughes, Philip D. Yin, Steven Schnittman

Research output: Contribution to journal › Article › peer-review

98 Scopus citations

Fingerprint

Dive into the research topics of 'Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: A randomised study'. Together they form a unique fingerprint.

Medicine & Life Sciences